The Health Canada approval makes Amia the 1st automated peritoneal dialysis device cleared in the U.S. and Canada that includes voice guidance, touchscreen control and 2-way telemedicine features, Deerfield Park, Ill.-based Baxter said.
“As a leader in home dialysis, Baxter is committed to understanding patients’ and clinicians’ needs, so we can provide innovative therapy options that are designed to support access to care where and when it’s needed,” Baxter Canada head Stephen Thompson said in prepared remarks. “Baxter’s Amia with Sharesource system is uniquely designed to help more patients self-administer home PD therapy and allow healthcare providers the ability to remotely manage their patients’ care.”
Earlier this month, Baxter CEO Jose Almeida said the company is getting out of the home hemodialysis business, ceding the field to market leader NxStage Medical (NSDQ:NXTM).
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.